NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

UPB

Upstream Bio Inc

Jul 15 • 02:10PM ET

11.37

Dollar change -0.36
Percentage change -3.06	%

Healthcare • Biotechnology • USA • NASD

Held by: IWM VTI IWN VXF SCHA VTWO FESM SBIO RSSL AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	63.99%	Shs Outstand	53.64M	Perf Week	4.32%
Market Cap	611.67M	Forward P/E	-	EPS next Y	-2.92	Insider Trans	0.00%	Shs Float	19.37M	Perf Month	-1.64%
Enterprise Value	181.99M	PEG	-	EPS next Q	-0.61	Inst Own	48.33%	Short Float	21.22%	Perf Quarter	54.28%
Income	-	P/S	-	EPS this Y	53.97%	Inst Trans	3.81%	Short Ratio	10.16	Perf Half Y	-17.00%
Sales	-	P/B	1.37	EPS next Y	-13.68%	ROA	-	Short Interest	4.11M	Perf YTD	-30.84%
Book/sh	8.31	P/C	1.42	EPS next 5Y	21.99%	ROE	-	52W High	29.46 -61.40%	Perf Year	-
Cash/sh	8.02	P/FCF	-	EPS past 3/5Y	-78.90% -	ROIC	-	52W Low	5.14 121.22%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.84% -	Gross Margin	-	Volatility	5.44% 6.69%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.71	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	47.43	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.46	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	47.43	EPS Q/Q	-	SMA20	2.45%	Beta	-	Target Price	55.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	10.87%	Rel Volume	0.28	Prev Close	11.73
Employees	52	LT Debt/Eq	0.00	Earnings	May 06 BMO	SMA200	-14.80%	Avg Volume	404.43K	Price	11.37
IPO	Oct 11, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.16% 73.46%	Trades		Volume	83,902	Change	-3.06%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-05-24	Initiated	William Blair	Outperform
Nov-05-24	Initiated	TD Cowen	Buy
Nov-05-24	Initiated	Piper Sandler	Overweight	$75
Nov-05-24	Initiated	JP Morgan	Overweight	$38

Jul-09-25 09:00AM	First subject dosed in Upstream Bios Phase II trial of verekitug for COPD (Clinical Trials Arena) +7.34%
Jul-08-25 07:00AM	Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) (GlobeNewswire)
Jun-15-25 07:45AM	Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor (GlobeNewswire)
Jun-05-25 07:00AM	Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 (GlobeNewswire)
Jun-04-25 07:00AM	Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
07:00AM	Loading…
May-20-25 07:00AM	Upstream Bio Appoints Stacy Price as Chief Technology Officer (GlobeNewswire)
May-06-25 07:00AM	Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs (GlobeNewswire) -5.41%
Apr-17-25 05:51PM	Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent (Seeking Alpha) +10.59%
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-12-25 07:00AM	Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +7.83%
Feb-25-25 08:00AM	Upstream Bio to Present at Upcoming March Investor Conferences (GlobeNewswire) -5.96%
Feb-11-25 09:00AM	Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps (PR Newswire)
Jan-06-25 08:00AM	Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.47%
Dec-17-24 08:00AM	Upstream Bio Appoints Allison Ambrose as General Counsel (GlobeNewswire)
Dec-16-24 08:00AM	Upstream Bio Announces Addition to Russell 2000 Index (GlobeNewswire) -6.12%
08:00AM	Loading…
Nov-21-24 08:00AM	Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-08-24 07:11AM	Upstream Bio reports Q3 revenue $607,000 vs $621,000 last year (TipRanks)
Nov-07-24 07:00AM	Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-17-24 07:02PM	Orbimed Advisors LLC Acquires New Stake in Upstream Bio Inc (GuruFocus.com) +9.66%
Oct-15-24 04:15PM	Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +6.27%
Oct-10-24 07:35PM	Upstream Bio Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chimovits Erez	Director	Oct 15 '24	Buy	17.00	825,000	14,025,000	4,554,873	Oct 17 04:19 PM
ORBIMED ADVISORS LLC	Director	Oct 15 '24	Buy	17.00	825,000	14,025,000	4,554,873	Oct 17 04:17 PM
AI Upstream LLC	10% Owner	Oct 15 '24	Buy	17.00	1,175,000	19,975,000	1,175,000	Oct 17 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UPB

Upstream Bio Inc

Upgrade your FINVIZ experience